ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Total pancreatectomy (TP), Partial pancreaticoduodenectomy (PD).
- Кому может быть актуально
- Состояния в реестре: Pancreatic Cancer. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Германия, Швейцария
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer: a Multi-centric Randomized Controlled Trial
Обзор
The goal of this clinical trial is to learn if total removal of the pancreas is a preferable alternative to partial removal in patients with cancer of the pancreatic head who are at high risk of pancreatic leakage. The main question it aims to answer is: Does total pancreas removal improve survival without reducing quality of life compared to partial removal? The only study specific procedures are the collection of 2 blood samples (7.5ml for each time point, preoperatively and during the hospitalisation) and the completion of the questionnaires.
Подробное описание
The pancreas is located in the upper abdomen and has 2 main functions: Production of digestive juices and of insulin, the latter being most important for blood sugar regulation and energy conservation. Certain types of cancer in the pancreatic head are very aggressive, but with complete surgical removal of the tumor and additional chemotherapy cure is possible. For tumor resection, the head of the pancreas as well as duodenum and part of the bile duct are removed. 3 new connections are built: the remaining pancreas, bile duct and stomach are connected to a loop of small intestine.
This operation takes around 6 hours and leads to complications in 20-30% of cases. A serious complication and unfortunately the most frequent is the leaking of the pancreas remnant, with outflow of the aggressive digestive juice into the surrounding tissue. Consequences may be severe bleeding and/or infections. Many studies show that affected patients have an increased risk of tumor recurrence and a reduced survival.
To avoid pancreatic leak, the entire pancreas can be removed. So far, removal of the whole pancreas has only been chosen in cases of very advanced cancer. After both, partial or total pancreas removal, patients need to substitute digestive enzymes. This can be done by capsules, which need to be taken with every meal. But while some patients after partial removal maintain sufficient function to produce insulin, all patients after total removal are diabetic and need insulin injections. In the past, blood sugar control in the absence of insulin production was difficult and accompanied by low quality of life (QoL). This has changed tremendously by the introduction of continuous glucose monitoring (sensors, which are attached to the arm) and automated insulin delivery systems (also known as "artificial pancreas"). This development renders total pancreas removal a reasonable alternative, with the advantage, that only 2 new connections are made: One between the bile duct and small intestine and one between the stomach and the small intestine.
Study question: Is removal of the whole pancreas in patients at high risk of a pancreatic leakage a preferable alternative to partial removal?
For this study, patients with cancer of the pancreatic head who are planned for surgery can be included. These patients will be randomly assigned to two groups:
1. Standard group: partial removal of the pancreas 2. Study group: total removal of the pancreas
Both techniques are safe and are established techniques to treat cancer in the pancreatic head. After the operation, many clinical data will be recorded. The two most important factors will be survival and quality of life, which will be assessed by questionnaires on a regular base. Additionally, postoperative complications, chemotherapy rates, tumor recurrence and many more data will be monitored.
Вмешательства
- Процедура Total pancreatectomy (TP)
The investigators perform TP in patients who undergo surgical resection of a malignant tumor in the pancreatic head. - Процедура Partial pancreaticoduodenectomy (PD)
The investigators perform partial PD with anastomosis of the pancreas in patients who undergo surgical resection of a malignant tumor in the pancreatic head. This is the current standard procedure.
Первичные конечные точки
- Overall survival (OS) [Срок оценки: At 2 years]
Вторичные конечные точки (12)
- Quality of Life (QoL) Pancreatic Cancer [Срок оценки: At 0.5 year, at 1 year, at 2 years]
- Quality of Life (QoL) Diabetes [Срок оценки: At 0.5 year, at 1 year, at 2 years]
- Postoperative complications (discriminating minor and major complications) [Срок оценки: Within 90 day of surgery]
- Mortality [Срок оценки: Within 90 days of surgery]
- Length of hospital stay in days [Срок оценки: Within 90 days of surgery]
- Re-admission [Срок оценки: Within 90 days of surgery]
- Re-operation [Срок оценки: Within 90 days of surgery]
- Adjuvant Chemotherapy (ACT) initiation [Срок оценки: At 1 year]
- Adjuvant Chemotherapy (ACT) completion [Срок оценки: At 1 year]
- Disease-Free Survival (DFS) [Срок оценки: At follow-up, up to 4.5 years]
- Functional status [Срок оценки: At 0.5 year, at 1 year, at 2 years]
- Body Mass Index (BMI) [Срок оценки: At 0.5 year, at 1 year, at 2 years]
Критерии участия
Критерии включения
- Adult patients (age ≥ 18 years) scheduled to undergo PD for highly suspected or histologically proven, resectable pancreatic ductal adenocarcinoma (PDAC), distal cholangiocarcinoma (DCC), and/or ampullary cancer (pancreaticobiliary type)
- Suspected pancreas anastomosis at high-risk for development of a postoperative pancreatic fistula (POPF) (grade "D" according to Schuh et al. (29): Estimation by CT scan, MRI, and/or Endoscopic Ultrasound
- Written informed consent
Критерии исключения
- Duodenal carcinoma, ampullary cancer (intestinal type), neuroendocrine tumors, benign tumors, chronic pancreatitis
- Medical conditions that do not allow appreciation of the nature, scope, and possible consequences of the trial as judged by the investigator
- Pregnancy. A beta-Human Chorionic Gonadotropin (bHCG) pregnancy test must to be performed for women of child-bearing potential (defined as premenopausal women who have not undergone surgical sterilization)
- Inability to follow the study procedures, e.g., due to psychological disorders, dementia, etc.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Рандомизированное
- Модель
- Параллельные группы
- Маскирование
- Открытое
- Основная цель
- Лечение
Центры проведения
Швейцария · 8 центров
- Department of General and Visceral Surgery, Kantonsspital Aarau — Aarau
- Department of Surgery, Kantonsspital Baden — Baden
- Department of Visceral Surgery, University Hospital Basel — Basel
- Inselspital, Bern University Hospital — Bern
- Department of Visceral Surgery, University Hospital Geneva — Geneva
- Department of General, Visceral, Endocrine and Transplantation Surgery, Kantonsspital St. — Sankt Gallen
- Department of Surgery, Stadtspital Triemli Zürich — Zurich
- Department of Surgery and Transplantation, University Hospital Zürich — Zurich
Германия · 2 центра
- Department of General, Visceral and Transplantation Surgery, University Hospital Münster — Münster
- Department of General and Visceral Surgery, University Hospital Ulm — Ulm
Идентификаторы
NCT: NCT06801899 · 2024-02010